JVS DIAGNOSTICS llc took part in Russian Oncological CongressThe report "The possibility to use the epithelial carcinoma marker CA-62 for the early detection of malignant epithelial tumors" during Skolkovo session headed by the Academician Alexander G. Rumyantsev was done in Russian Oncological Congress by Janneta R. Tcherkassova - the JVS CEO. https://rosoncoweb.ru/events/2018/11/13/program/
JVS DIAGNOSTICS llc during the Open Innovations 2018 has declared the finalizing the first round of investments
The UCT inc Toronto, Canada has finished the first round of investments to develop its JVS Diagnostics subsidiary. This declaration was done during Open Innovations Forum and shared by media. The first press release was published by Forbes Russia www.forbes.ru/tehnologii/368185-kak-obnaruzhit-rak-400-000-na-samyy-tochnyy-onkologicheskiy-test. Also The Skolkovo Innovation Center has shared it's own press release http://sk.ru/news/b/pressreleases/archive/2018/10/19/rezident-skolkovo-poluchil-ot-investorov-400-ty...
JVS DIAGNOSTICS llc Took Part in Open Innovations 2018
JVS Diagnostiks llc has represented its project at the Open Innovations Venue at Skolkovo Innovaion Center Technopark. The Forum has become a unique international platform for discussion bringing together tech entrepreneurs, scientists, leading experts, students, government officials and corporations from different countries and regions.
JVS DIAGNOSTICS llc has recieved the ISO 13485 Certifiate
The Oncomarker project has recieved the ISO 13485 Certificate for it's IC Skolkovo facility. The obtaining of such certification is significally important to develop state of the art diagnostics tool.
JVS DIAGNOSTICS llc have launched the lab in the IC Skolkovo
The Onkomarker project has started it's laboratory facility in technopark of Skolkovo Innovation Center. The space consist of analitycal and GMP clear labaratory. The lab is required to be in line with new ISO 13485 requirments.
JVS DIAGNOSTICS llc have presented it's project at StartupVillage-2018
Despite the strong wind on the last day of May and the bad weather, we did not have to complain about the small number of visitors to our stand. In total, more than 150 people from more than 100 companies visited the stand in two days. More than 30 of the visitors left their coordinates for further interaction, and not less than half of them showed an interest in investing in the project. A large number of guests who visited our stand could be called potential consumers of the product we brought to the market. They were interested in the time-to-market, many were ready to be tested in the near future. Despite our skepticism, on the second day of the exhibition there were many interesting meetings up to the very end of the exposition, and interest to our results was very serious and often, professional. The weather seemed to wish us success and the sun accompanied us, giving a good mood.
The project received the
status of Skolkovo. The JVS Diagnostics LLC has recieved $140,000 from private
investors in Canada through a member, UCT Research and Development Inc.,
To this date, all the unique components of the test kit have been developed such as monoclonal antibodies Mab, CA-62 antigen, Standard calibrators, and buffer solutions.
Quality controls have been developed and standard protocols have been written. A patent application has been prepared.
The dynamics of the MEC cancer marker was studied on 500 Russian patients with stage III-IV gastric cancer and SCL, who underwent chemotherapy at the N.N. Blokhin Russian Cancer Research Center.
A research laboratory was opened at the N.N. Blokhin Russian Cancer Research Center. The technology “MEC” was tested on samples of 600 patients with prostate, breast, ovarian and stomach cancer from the Institute of Clinical Chemistry and Biochemistry, India.